A Rational Engineering Strategy for Designing Protein A-Binding Camelid Single-Domain Antibodies

• Kevin A. Henry,

  Affiliation Human Health Therapeutics Portfolio, National Research Council Canada, 100 Sussex Drive, Ottawa, Ontario, Canada, K1A 0R6

  ⨯
• Traian Sulea,

  Affiliation Human Health Therapeutics Portfolio, National Research Council Canada, 6100 Royalmount Avenue, Montreal, Quebec, Canada, H4P 2R2

  ⨯
• Henk van Faassen,

  Affiliation Human Health Therapeutics Portfolio, National Research Council Canada, 100 Sussex Drive, Ottawa, Ontario, Canada, K1A 0R6

  ⨯
• Greg Hussack,

  Affiliation Human Health Therapeutics Portfolio, National Research Council Canada, 100 Sussex Drive, Ottawa, Ontario, Canada, K1A 0R6

  ⨯
• Enrico O. Purisima,

  Affiliation Human Health Therapeutics Portfolio, National Research Council Canada, 6100 Royalmount Avenue, Montreal, Quebec, Canada, H4P 2R2

  ⨯
• C. Roger MacKenzie,

  Affiliations Human Health Therapeutics Portfolio, National Research Council Canada, 100 Sussex Drive, Ottawa, Ontario, Canada, K1A 0R6, School of Environmental Sciences, University of Guelph, 50 Stone Road East, Guelph, Ontario, Canada, N1G 2W1

  ⨯
• Mehdi Arbabi-Ghahroudi

  * E-mail: mehdi.arbabi@nrc-cnrc.gc.ca

  Affiliations Human Health Therapeutics Portfolio, National Research Council Canada, 100 Sussex Drive, Ottawa, Ontario, Canada, K1A 0R6, School of Environmental Sciences, University of Guelph, 50 Stone Road East, Guelph, Ontario, Canada, N1G 2W1, Department of Biology, Carleton University, 1125 Colonel By Drive, Ottawa, Ontario, Canada, K1S 5B6

  ⨯